PB1883: TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINOTUZUMAB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS INDUCES DEEP REMISSIONS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL.

PB1883: TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINOTUZUMAB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS INDUCES DEEP REMISSIONS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL.

Bibliographic Details
Main Authors: J. Burger, M. Sivina, E. Kim, G. Issa, W. Wierda, N. Jain, P. Thompson, A. Ferrajoli
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000850384.35364.fa

Internet

http://journals.lww.com/10.1097/01.HS9.0000850384.35364.fa

Similar Items